Targeted therapy, aiming, for instance, at antitumor treatments, can be divided into active and passive forms [ 72, 73 ]. Passive targeting is based on higher vascularity and higher vascular permeability of the tumor, as well as inflamed tissues, compared to physiological ones [ 73, 74 ]. Additionally, the lymphatic circulation of the tumor shows decreased efficiency [ 25 ], which led to easier accumulation of nanoparticles in the tumor or inflamed tissues [ 10, 27, 72, 74 ]. This passive accumulation is normally called "ELVIS" (Extravasation through Leaky Vasculature and later Inflammatory cell-mediated Sequestration) [ 72, 74 ]. From the facet of surface qualities, negatively charged nanoparticles accumulate less effectively inside cells, due to the negatively charged cell membrane, which slows down the cellular uptake, so, in this case, a neutral surface charge is more favorable [ 25 ]. In contrast, active targeting can be accomplished by functionalizing the outer surface of the silica carriers [ 10, 27, 72 ], where molecules are attached to the surface of the carriers that specifically bind to certain cell surface ligands and receptors, which are characteristic of tumor-, but not of healthy cells. This selective method provides more effective treatment and reduces the side impacts of cytotoxic APIs on healthy cells and tissues [ 10, 27 ]. The most recent findings on active targeting possibilities are summarized in Table 3. García-Fernández et al. prepared a mesoporous silica-based nanocarrier loaded with dexamethasone and capped with a particular protein to actively target the TNFR1 receptor, which is overexpressed in pro-inflammatory macrophages [ 72 ]. Since the carriers are preferably internalized by these macrophages, the cargo is released in a controlled manner, during enzymatic hydrolysis, thus preventing premature drug release, thanks to the gatekeepers. The targeting talent was tested in vitro with activated macrophages. On the other hand, the therapeutic efficiency was tested in vivo in mouse models. The researchers observed greater therapeutic impacts and fewer adverse side influences than in the case of free dexamethasone. To sum up, dexamethasone-loaded MSN has been effectively developed to actively target the lungs in acute lung injury (ALI), and this result may also be promising in other lung diseases (COPD, asthma) [ 72 ]. Teruel et al. presented a novel approach in oral inflammatory bowel sickness (IBD) therapy, using functionalized magnetic mesoporous silica microparticles [ 75 ].
Silica for Optical Fiber: Purity Requirements and Manufacturing Role
Kaolin vs Silica: Filler Properties, Uses and Selection Guide
85. Patiño-Herrera R., Louvier-Hernández J.F., Escamilla-Silva E.M., Chaumel J., Escobedo A.G.P., Pérez E. Prolonged release of metformin by SiO2 nanoparticles pellets for type II diabetes control. Eur. J. Pharm. Sci. 2019;131:1-8. doi: 10.1016/j.ejps.2019.02.003. [ DOI ] [ PubMed ] [ Google Scholar ]
What Is Hydrophilic Silica? Properties, Grades and Applications
32. Voicu S.N.P., Dinu D., Sima C., Hermenean A., Ardelean A., Codrici E., Stan M.S., Zărnescu O., Dinischiotu A. Silica nanoparticles induce oxidative stress and autophagy but not apoptosis in the MRC-5 cell line. Int. J. Mol. Sci. 2015;16:29398-29416. doi: 10.3390/ijms161226171. [ DOI ] [ PMC free piece ] [ PubMed ] [ Google Scholar ]
Barium Sulfate vs Silica: Fillers for Coatings and Plastics Compared
Sibelco Quartz: Product Range, Purity Grades and Applications
Precipitated Silica Market 2026: Size, Tire Demand and Growth Forecast
What is silica (SiO₂)?
silica particle size
31. Ismail A., Sial N., Rehman R., Abid S., Ismail M.S. Survival, expansion, behavior, hematology and serum biochemistry of mice under different concentrations of orally administered amorphous silica nanoparticle. Toxicol. Rep. 2023;10:659-668. doi: 10.1016/j.toxrep.2023.05.006. [ DOI ] [ PMC free piece ] [ PubMed ] [ Google Scholar ]
What is the difference between fumed silica and precipitated silica?
scratch resistant silica
9. Mitran R.A., Deaconu M., Matei C., Berger D. Nanocarriers for Drug Delivery: Nanoscience and Nanotechnology in Drug Delivery. Elsevier Science Ltd.; Amsterdam, The Netherlands: 2018. Mesoporous Silica as Carrier for Drug-Delivery Systems; pp. 351-374. [ Google Scholar ]
What drives silica raw material prices?
silicon carbide
58. Kinnari P., Mäkilä E., Heikkilä T., Salonen J., Hirvonen J., Santos H.A. Comparison of mesoporous silicon and non-ordered mesoporous silica materials as drug carriers for itraconazole. Int. J. Pharm. 2011;414:148-156. doi: 10.1016/j.ijpharm.2011.05.021. [ DOI ] [ PubMed ] [ Google Scholar ]
Cite this article: Silica Raw Materials News. "Silica Price in 2026: Cost by Type, Grade and Key Price Drivers
." Published 2026-11-20 11:02:46. /news/article.html Disclaimer: Prices and data are for reference only and do not constitute purchasing or investment advice. Please credit the source when republishing.